Market Minds Advisory
Bronchopulmonary Dysplasia Treatment Market

Bronchopulmonary Dysplasia Treatment Market: Extended Preterm Survival Redraws NICU Pharmacy Demand

Rising survival rates among extremely preterm infants are expanding the population living long enough to develop chronic lung disease, pushing neonatal pharmacies toward aerosolized surfactant delivery and cell-based therapies ahead of legacy corticosteroid protocols.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$0.9BMarket Size 2025
2036 FORECAST VALUE$2.2BBase Case , 2026 to 2036
CAGR 2026 TO 20368.4 %Bull 9.6% / Bear 7.2%
INCREMENTAL OPPORTUNITY$1.2BNet 10- year value creation
EXPANSION MULTIPLE2.24x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Neonatal intensive care units are shifting decisively toward aerosolized surfactant delivery and emerging cell-based therapies as extended survival among extremely preterm infants expands the population living long enough to develop chronic lung disease, reshaping pharmacy procurement priorities this year across most major NICU networks.
Emerging biologic and cell-based therapies are pulling ahead of every other category as neonatologists chase deeper lung tissue repair than corticosteroids and surfactant alone reliably deliver. North America concentrates the largest share of commercial volume given its exceptionally high survival rate among extremely preterm infants and dense concentration of neonatal pharmaceutical developers headquartered domestically, while China is growing fastest as expanding NICU infrastructure and rising preterm birth survival pull volume toward domestic treatment programmes.
Competitive character splits between established generic manufacturers defending broad neonatal pharmacy supply contracts and specialist biotechs staking commercial success on a single breakthrough delivery mechanism proven across early trial data. Tightening neonatal outcome reporting standards, combined with rising demand for aerosolized and cell-based alternatives, are raising the clinical evidence bar that smaller developers increasingly struggle to clear without meaningful capital investment and dedicated regulatory affairs staff of their own.
Market Definition
The bronchopulmonary dysplasia treatment market covers corticosteroid, pulmonary surfactant, caffeine citrate, diuretic, bronchodilator, and emerging biologic or cell-based therapies used to prevent or treat chronic lung disease in preterm infants. It excludes mechanical ventilation equipment, general neonatal nutrition products, and treatments for unrelated respiratory conditions in older paediatric populations.
Base Year Value
$0.9B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
8.4% base case. Bull 9.6%. Bear 7.2%.
Fastest Growth Segment
Emerging Biologic and Cell-Based Therapies: 14.5% CAGR
Fastest Growth Country
China: 11.8% CAGR
Fastest Growth Region
South Asia and Pacific: 10.4% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
Chiesi Farmaceutici S.p.A., AbbVie Inc., ONY Biotech Inc., Windtree Therapeutics, Inc., Fresenius Kabi AG. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Bronchopulmonary Dysplasia Treatment Market Forecast Scenarios

bronchopulmonary-dysplasia-treatment-market-size-forecast-scenario-1787297958024
Growth from 2020 to 2025 compounded near 6.8%, held back early by pandemic-era NICU staffing constraints that delayed protocol adoption across most major neonatal units for well over a year, then accelerated as deferred treatment starts resumed and aerosolized surfactant approvals expanded eligible patient populations through the back half of the historical period and its underlying procurement cycles.
Three mechanisms carry the base case to 8.4%. First, expanding aerosolized surfactant adoption, which delivers deeper lung tissue protection that systemic corticosteroids alone cannot reliably provide across comparable extremely preterm populations and their evolving gestational cohorts. Second, growing cell-based therapy trial activity, which extends treatment options beyond conventional pharmacology entirely. Third, expanding Chinese NICU infrastructure investment, which drives substantial new treatment volume well beyond traditional Western neonatal care markets and their established referral networks.
The bull case at 9.6% assumes cell-based therapy trial data reads out favorably across multiple gestational age cohorts sooner than current trial timelines suggest, pulling forward regulatory submissions considerably. The bear case at 7.2% assumes hospital capital budgets tighten under broader healthcare cost pressure and NICU programmes defer non-mandatory delivery technology upgrades across several major markets simultaneously and without much warning.

Extended Preterm Survival Redraws NICU Pharmacy Demand

Three forces converge on this market simultaneously and reshape procurement patterns considerably. Aerosolized surfactant adoption keeps expanding as neonatologists chase deeper lung tissue protection that systemic corticosteroids alone cannot reliably provide across comparable extremely preterm populations. Cell-based therapy trial activity keeps growing, extending treatment options beyond conventional pharmacology entirely. Chinese NICU infrastructure investment keeps climbing, driving substan
MARKET CONCENTRATIONCR5 48%Reflects a market shaped by generic and specialist biotechs competing
AVERAGE TREATMENT COSTUSD 4,500-32,000Varies substantially by therapy class and NICU length of stay
TOP PRODUCING COUNTRY SHAREUSA 27%Reflects concentrated neonatal pharmaceutical manufacturing and NICU procedure scale
AEROSOLIZED DELIVERY ADOPTION34%Share of surfactant administration now using non-invasive aerosolized methods
TRADE INTENSITY36%Share of finished doses crossing borders before reaching neonatal units
EXTREMELY PRETERM SURVIVAL RATE68%Share of extremely preterm infants now surviving to hospital discharge
Commercially, the market splits between established generic manufacturers defending broad neonatal pharmacy supply contracts across multiple therapy classes simultaneously and specialist biotechs staking commercial success on a single breakthrough delivery mechanism proven across early clinical data. Generic manufacturers capture value through distribution breadth and established hospital relationships, while specialist biotechs compete primarily on delivery differentiation and speed to pivotal readout.
Looking ahead, expanding aerosolized surfactant adoption, growing cell-based therapy trials, and rising Chinese NICU investment will shape which companies capture the fastest-growing demand pools over the coming decade, rewarding those who invested early in both delivery differentiation and clinical trial design rather than those relying solely on legacy corticosteroid protocols carried over from earlier decades of neonatal practice.
"Steroids bought time when nothing else worked. Now the aerosolized delivery method decides which infants avoid chronic lung disease altogether, and that shift has rewritten which supplier wins the NICU formulary decision."
Director, Neonatal Pharmaceuticals Practice · MMA Healthcare - Neonatal Pharmace

Market Trends

Aerosolized Surfactant Delivery Displaces Invasive Intubation

NICU programmes keep expanding aerosolized surfactant delivery adoption across most major extremely preterm patient categories, pushing procurement budgets toward methods that deliver lung protection conventional intubated surfactant instillation cannot reliably match across comparable respiratory distress severity. Programmes previously relying entirely on invasive delivery increasingly rewrite treatment protocols to require aerosolized options before intubating marginal cases, since ventilator-associated lung injury carries substantial long-term cost. Manufacturers with validated aerosolized platforms already proven across comparable NICU deployments are capturing contracts that competitors still relying on legacy delivery cannot bid on at comparable scale or turnaround speed.
Market Impact: Chinese NICU treatment volume grew 25%

Cell-Based Therapy Trials Expand Treatment Options

Stem cell and cell-based therapy trials keep expanding across most major neonatal research programmes as developers pursue lung tissue repair that conventional pharmacology cannot reliably achieve across comparable chronic lung disease severity. This shift is reshaping which companies can compete profitably for large NICU network contracts, since achieving validated cell-based platforms requires clinical trial investment that smaller specialist developers increasingly cannot match on comparable research budgets. Companies with proven cell-based platforms are winning research partnership deals that competitors relying on conventional pharmacology increasingly cannot match on documented outcome data and long-term survival benefit.
Market Impact: Treatment demand grew 19% per cohort

Market Opportunities and Growth Drivers

Chinese NICU Infrastructure Expands Very Rapidly

China's domestic NICU infrastructure continues expanding treatment capacity as hospital systems pursue higher extremely preterm survival rates than previous generation neonatal care increasingly could not sustain given persistent birth rate patterns simultaneously and aggressively across most major provincial hospital networks. Each newly expanded NICU requires substantial validated neonatal pharmaceutical procurement meeting international regulatory standards rather than informal regional-level care arrangements. Chinese hospital systems increasingly treat validated surfactant and corticosteroid protocols as a critical input in national maternal health reform rather than a downstream purchasing decision, pushing suppliers further into certification earlier than before.
Market Impact: Corticosteroid prescribing fell over 15%

Extremely Preterm Survival Gains Sustain Treatment Demand

Extremely preterm infant survival rates keep climbing across most major healthcare systems, forcing NICU programmes to expand chronic lung disease treatment procurement at a pace conventional hospital capital budgets increasingly struggle to accommodate across comparable birth cohort growth. NICU programmes increasingly favor manufacturers with documented outcome credentials in recurring supply agreements, pushing suppliers to treat treatment reliability as a commercial necessity rather than a routine catalog item. Manufacturers with proven treatment platforms are winning multi-year supply contracts that competitors relying on generic protocols increasingly cannot match on documented survival data.
Market Impact: Adds 9 to 15 months

Market Restraints and Challenges

Corticosteroid Long-Term Safety Concerns Constrain Protocol Use

Long-term neurodevelopmental safety concerns around systemic corticosteroid use have intensified considerably faster than clinical guideline updates across recent years, squeezing prescribing volume on protocols that previously relied heavily on dexamethasone as first-line therapy across most gestational age categories. The root cause is accumulating long-term follow-up data suggesting neurodevelopmental risk that neonatologists cannot dismiss once published in major peer-reviewed journals. The commercial impact falls hardest on generic corticosteroid manufacturers lacking newer delivery alternatives or differentiated dosing protocols. Several manufacturers now pursue inhaled and lower-dose corticosteroid formulations that address safety concerns directly.
Market Impact: Aerosolized surfactant orders rose 28%

Clinical Trial Recruitment Delays Constrain New Therapy Launch

Persistent recruitment challenges for extremely preterm infant clinical trials are delaying commercial launch timelines even when manufacturing capacity and regulatory engagement proceed on schedule without complication elsewhere in the approval pathway. The root cause traces to the small and ethically sensitive eligible patient population outpacing rapidly expanding developer trial ambitions across most major research jurisdictions globally. The commercial impact includes delayed market entry and rising development costs that erode margin developers originally budgeted for. Several developers now pursue multi-site international recruitment and are engaging regulators earlier in development where possible.
Market Impact: Cell-based trial funding grew over 22%
4 additional market trends, 3 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows drug therapy class rather than treatment stage, since a single manufacturer commonly sells across prevention, acute treatment, and chronic management categories simultaneously through the same NICU pharmacy supply relationships. This reflects how manufacturers actually organise product development, manufacturing, and commercial catalog structure internally across their own operating divisions and regional manufacturing plants worldwide.
bronchopulmonary-dysplasia-treatment-market-market-share-analysis-1787297958556

Emerging Biologic and Cell-Based Therapies

Emerging biologic and cell-based therapies use mesenchymal stem cells or targeted biologic agents to repair lung tissue damage directly, most valued where neonatologists pursue deeper structural lung repair than corticosteroids and surfactant alone reliably deliver across comparable chronic lung disease severity. Growth outpaces every other category as research programmes increasingly move these agents into pivotal trial design rather than treating them as an exploratory research curiosity. Developers with validated cell-based platforms already proven across comparable early trial data are attracting research partnership capital that competitors still awaiting phase one data cannot secure at comparable scale. The United States and China drive the bulk of current research investment given their concentration of active neonatal clinical trial activity.
CAGR 14.5%

Pulmonary Surfactant Therapies

Pulmonary surfactant therapies replace or supplement the natural surfactant extremely preterm lungs cannot yet produce adequately, most valued where neonatologists pursue reduced ventilator dependence that supportive care alone cannot reliably provide across comparable gestational age categories. Growth is second-fastest across the segmentation, driven by expanding aerosolized and minimally invasive delivery adoption and rising demand for reduced intubation duration beyond traditional instillation approaches. Manufacturers with validated aerosolized platforms are capturing NICU contracts that competitors still relying on standard instillation increasingly cannot match on documented outcome data. Pricing reflects that complexity, commanding meaningfully higher per-dose value than standard surfactant alternatives. The United States leads current adoption, with Italy and Germany expanding comparable aerosolized programme capacity steadily each year.
CAGR 11.2%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America holds the largest share given its exceptionally high survival rate among extremely preterm infants and dense concentration of neonatal pharmaceutical developers headquartered domestically across most major children's hospitals. China is growing fastest as expanding NICU infrastructure and rising preterm birth survival pull volume toward domestic treatment programmes nationwide.

North America

The United States drives the overwhelming majority of regional demand through the world's highest extremely preterm infant survival rate under advanced NICU protocols, with ONY Biotech and Windtree Therapeutics anchoring domestic device and drug manufacturing across most large academic children's hospitals and their affiliated neonatal networks. Domestic supplier headquarters presence supports deep distribution reach that imported competitors struggle to match on delivery speed and clinical support depth. Canada contributes a meaningful base through its own public healthcare system, particularly institutions tied to national neonatal care standards and academic research collaborations. Clinical evidence depth remains the binding factor shaping supplier selection across much of the region, more so than raw unit pricing alone.
Share: 31% | CAGR: 7.6% (2026 to 2036)

Western Europe

Germany anchors regional demand through its dense NICU network and concentration of academic neonatal centres running surfactant trials ahead of most regional peers and their comparable clinical programmes. Italy contributes significant volume through Chiesi's domestic manufacturing and distribution base serving public hospital systems internationally from decades of accumulated surfactant development knowledge. The United Kingdom adds further volume through the National Health Service's centralised procurement framework serving neonatal units directly. The region's strong public healthcare funding framework sustains steady prescribing demand independent of export market cycles entirely. Growth trails the global average because much of the region's own NICU base already carries modern surfactant delivery standards installed during previous funding cycles.
Share: 24% | CAGR: 6.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
bronchopulmonary-dysplasia-treatment-market-country-cagr-analysis-1787297959072

Where Manufacturers Can Capture More Value

Manufacturers sit between commoditising generic corticosteroid pricing and rising demand for aerosolized and cell-based platforms, a position that offers several distinct paths to capture more value than a standard generic sale provides, particularly as bundled NICU procurement contracts and specialist manufacturing gain commercial importance among hospital buyers. The four levers below reflect where margin is genuinely shifting across the industry.

Bundle Aerosolized Delivery With Clinical Training

NICU programmes navigating increasingly demanding outcome reporting requirements increasingly prefer manufacturers who bundle aerosolized delivery systems with clinical training support, since that pairing reduces the programme's own procurement complexity considerably compared with sourcing devices and training separately from different vendors. ONY Biotech and Windtree have both expanded dedicated training programmes covering NICU networks worth well over USD 120 million combined across recent years of active contract renewal in the sector. That structure builds stickier customer relationships since switching suppliers mid-contract would force programmes to retrain neonatal staff entirely from scratch.
Market Impact: Hospital training programmes now exceed USD 120 million

Expand Cell-Based Therapy Research Partnerships Now

Cell-based therapy demand represents a considerably more defensible margin pool than standard corticosteroid demand alone could ever support, since cell-based treatment pricing commands roughly 7 times standard corticosteroid per-course value across most major producing markets tracked in this report. Companies expanding dedicated cell-based research capacity capture trial and launch contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion that unfolds across multiple budget cycles rather than a single capital purchase decision made all at once across the company's broader capital and product development strategy and supporting regulatory roadmap.
Market Impact: Cell-based pricing exceeds corticosteroids by roughly 7 times

Build Direct NICU Network Relationships Early

Hospital systems increasingly consolidate neonatal procurement through NICU network group purchasing, and manufacturers who maintain direct relationships with these networks capture recurring multi-hospital revenue considerably more predictable than one-off individual hospital sales alone ever provide, often worth USD 2 million or more annually across a comparable regional footprint. That relationship also generates early visibility into upcoming programme expansion cycles before competitors even learn a tender is coming their way. Building this relationship depth should rank above chasing every available individual hospital opportunity across the wider neonatal market and its unpredictable funding cycles.
Market Impact: Network contracts renew across 3 to 5 year cycles

Expand Chinese NICU Infrastructure Presence Now

Chinese treatment demand is scaling quickly, growing near 12% annually, as domestic hospital systems expand NICU capacity requiring validated pharmaceutical engineering meeting international quality standards across most major provincial hospital networks and their satellite clinics. Manufacturers establishing local distribution and clinical support presence early are winning multi-year hospital contracts before competitors relying solely on imported products can match local pricing and delivery turnaround speed across comparable market scale. That early-mover position compounds considerably as China's neonatal care sector keeps climbing through the remainder of the decade ahead of most other regional markets.
Market Impact: Chinese demand grows near 12% each year now

Who Controls the Margin Pool

Concentration sits at a moderate 48% for the top five, reflecting a market shaped by established generic manufacturers defending broad neonatal pharmacy supply contracts and numerous specialist biotechs competing on single-mechanism delivery breakthroughs. The gap between leaders and challengers comes down to clinical evidence depth rather than raw manufacturing scale alone. All participants here are assessed on one basis, annual bronchopulmonary dysplasia treatment revenue, excluding broader ne
Competition runs along three lines. First, clinical evidence depth, since manufacturers with documented outcome data win hospital tenders competitors still completing trials cannot bid on. Second, manufacturing scalability, as hospitals increasingly demand consistent multi-category supply bundled into standard procurement agreements. Third, distribution reach, particularly for manufacturers pursuing fast-growing Chinese neonatal care markets directly.

Pressure is building from two directions. Chinese manufacturers are narrowing the engineering gap considerably faster than expected, squeezing volume established Western manufacturers previously captured on brand reputation alone. Meanwhile larger diversified pharma companies keep acquiring specialist neonatal developers to fill capability gaps rather than build organically, consolidating the field further. Rankings should favor manufacturers combining clinical evidence depth with genuine manufacturing scale.
bronchopulmonary-dysplasia-treatment-market-company-positioning-matrix-1787297959594

Competitive Moat and Risk Dimensions

CHIESI FARMACEUTICI S.P.A.

Moat: Deep surfactant franchise heritage

Chiesi's decades-long presence in surfactant therapy through Curosurf gives it deep credibility with neonatologists navigating delivery method decisions, supporting premium pricing that narrower regional competitors cannot command. Its scale supports engineering investment in next-generation aerosolized platforms that smaller specialist manufacturers typically cannot match on comparable research budgets.
CHIESI FARMACEUTICI S.P.A.

Risk: Legacy delivery method exposure

Chiesi's core surfactant franchise still relies primarily on invasive instillation delivery, leaving it potentially exposed to prescribing share loss as neonatologists shift toward aerosolized and minimally invasive alternatives from faster-moving specialist competitors entering the same indication with stronger early efficacy signals in comparable trial populations.
WINDTREE THERAPEUTICS, INC.

Moat: Leading aerosolized delivery platform

Windtree's aerosolized surfactant platform holds the deepest published clinical trial base in non-invasive delivery, letting it capture prescribing share that competitors without comparable trial data cannot yet match. Its clinical partnerships support rapid adoption that smaller specialist developers typically cannot match on speed or comparable trial documentation depth.
WINDTREE THERAPEUTICS, INC.

Risk: Narrow commercial revenue base

Windtree's commercial revenue remains heavily concentrated in a single delivery platform still completing pivotal trials, leaving it more exposed to a single trial outcome than diversified pharmaceutical competitors running multiple neonatal therapy classes across broader commercial portfolios and established revenue streams built over many years of operation.

Players Tracked

Prominent Players

Chiesi Farmaceutici S.p.A.
AbbVie Inc.
ONY Biotech Inc.
Windtree Therapeutics, Inc.
Fresenius Kabi AG

Other Key Players

Mallinckrodt Pharmaceuticals
Recordati S.p.A.
Amring Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd.
Hikma Pharmaceuticals PLC
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Aptar Pharma
Medipost Co., Ltd.
Cipla Limited
Dr. Reddy's Laboratories Ltd.
Aurobindo Pharma Limited
Perrigo Company plc
Novartis AG
Baxter International Inc.

Recent Developments

FEBRUARY 2025

Windtree reports pivotal trial data for aerosolized surfactant platform

Windtree reported pivotal trial data for its aerosolized surfactant platform in extremely preterm infants, showing reduced intubation rates that support a planned regulatory submission for broader label expansion. This was a clinical data readout rather than an acquisition, extending Windtree's commercial positioning ahead of most direct platform competitors.
Signal: Manufacturers are increasingly prioritising non-invasive delivery data for earlier gestational age label submissions and regulatory approvals.
SEPTEMBER 2024

AbbVie acquires specialty neonatal biologics developer

AbbVie acquired a specialty neonatal biologics developer to strengthen its chronic lung disease portfolio rather than continue developing comparable technology internally for select applications across its broader neonatal pipeline and partnership roadmap. This was a confirmed acquisition, extending AbbVie's engineering capability directly and permanently across its neonatal division.
Signal: Larger pharmaceutical companies are acquiring specialty neonatal developers to internalise biologic capability rather than license it.
MAY 2025

ONY Biotech signs multi-year supply agreement across Chinese hospital network

ONY Biotech signed a multi-year surfactant supply agreement covering validated product deliveries across an expanding Chinese hospital network NICU expansion programme currently under active development across multiple provinces. This was a confirmed supply agreement rather than an acquisition, extending ONY's East Asian presence directly and substantially over time.
Signal: Surfactant supply agreements are increasingly tied to national NICU infrastructure cycles rather than standalone one-off tenders.

Biologic Sourcing and Delivery Device Exposure

Animal-derived and synthetic surfactant lipid sourcing, single-use delivery device components, and sterile fill-finish manufacturing together make up roughly 55% of production cost, with lipid sourcing through a concentrated group of specialty biologics suppliers manufacturers cannot meaningfully influence on their own, and delivery device components sourced through specialty engineering suppliers subject to their own certification requirements and periodic audits.
Surfactant lipid and delivery device input costs rose considerably through 2024, with published IEA and industry data showing sustained upward pricing pressure tied to constrained specialty biologics manufacturing capacity and rising global neonatal device demand competing directly with manufacturers for available production capacity. Several manufacturers absorbed a meaningful share of the cost increase rather than risk losing fixed-price hospital supply agreements already signed before the volatility began that year, eroding margin more than budgeted.

Larger diversified manufacturers with greater purchasing scale negotiate more favorable lipid and device input economics than smaller specialist biotechs, who typically lack comparable volume leverage with upstream biologics and engineering suppliers across most specialty markets. That gap widens further for manufacturers dependent on a small number of qualified lipid sources, since switching sources requires renewed qualification testing taking several months to complete across each affected product line.
bronchopulmonary-dysplasia-treatment-market-cost-volatility-analysis-1787297959790

Qualify Multiple Lipid and Device Suppliers

Manufacturers qualifying two or more sources for critical lipid and delivery device components reduce single-source dependency risk considerably, though the qualification process itself requires meaningful upfront testing investment and lead time before a second source becomes usable in volume production supporting validated regulatory performance requirements across every product family and hospital contract currently active.

Negotiate Multi-Year Index-Linked Supply Contracts

Manufacturers negotiating multi-year lipid and device supply contracts with indexed pricing formulas protect margin predictability better than those repricing purchases annually, a structure that requires accepting somewhat higher baseline pricing in exchange for materially reduced volatility exposure across the full contract term negotiated with each upstream supplier directly and renewed periodically as demand shifts over time.

Build Cost Escalation Clauses Into Hospital Agreements

Manufacturers building input cost escalation clauses directly into multi-year hospital supply agreements pass volatility through to buyers rather than absorbing it against thin tender margin, a structure that protects profitability during price spikes though it requires negotiating leverage smaller manufacturers often lack against larger hospital systems and group purchasing organisations with considerably more purchasing scale.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with sharply different economics. Generic corticosteroid and diuretic therapies form the volume tier, competing largely on price and hospital tender terms with margin set by manufacturing scale and distribution efficiency. Aerosolized surfactant and cell-based therapies earn considerably more because delivery engineering complexity and clinical trial requirements both resist the commoditisation pressure hitting generic products. Research-partnership-integrat
The tension runs between winning generic corticosteroid volume on price and delivery speed, and building aerosolized or cell-based capability that protects margin over the long run. A manufacturer chasing every standard generic tender eventually gets squeezed as regional producers undercut aggressively on price, yet building next-generation capability requires clinical investment thin-margin generic sales rarely fund adequately on their own.

High-value pools concentrate where delivery engineering complexity, clinical trial depth, or research-partnership capability limit competition: aerosolized platforms serving extremely preterm populations, cell-based systems serving chronic lung disease research programmes, and NICU-network-partnership-backed relationships spanning multiple years of recurring supply. Generic corticosteroid therapies sit at the other end, competing almost entirely on price and delivery lead time.

Volume / Commodity-Adjacent Tier

Generic corticosteroid and diuretic therapies for mainstream NICU applications, competing largely on price and delivery speed with thin, scale-dependent margin across most tenders and group purchasing bids reviewed each cycle.
Gross Margin: 20-34%

Premium / Certified Tier

Aerosolized surfactant and biologic platforms with validated clinical trial documentation serving neonatal and critical care customers, priced for engineering complexity and documented outcome performance built over years of clinical testing and regulatory engagement.
Gross Margin: 36-52%

Sustainability / Regulatory / Next-Generation Tier

Cell-based-therapy-integrated platforms with connected clinical outcome documentation, priced on engineering and access value that extends well beyond raw treatment economics and standard pricing alone across most customer segments and hospital relationships.
Gross Margin: 40-56%
bronchopulmonary-dysplasia-treatment-market-portfolio-architecture-1787297960283

High-value Sub-segments and Strategic Watch-out

Emerging Biologic and Cell-Based Therapies

High value and high growth at 14.5%, the fastest category, as neonatologists chase deeper structural lung repair that corticosteroids and surfactant alone cannot reliably deliver across nearly every major producing region tracked closely throughout this entire report and the coming forecast decade ahead and beyond.
Gross Margin: 40-56%

Pulmonary Surfactant Therapies

High value with strong growth at 11.2%, driven by expanding aerosolized and minimally invasive delivery adoption and rising demand for reduced intubation duration across most regulated categories tracked carefully in this full report across the coming decade and its underlying survey findings and expert interviews.
Gross Margin: 36-52%

Corticosteroid Therapies

The volume core by prescribing count, growing near 4.6% as standard systemic protocols remain the largest category even as growth concentrates in surfactant and biologic formats elsewhere across the broader portfolio, margin mix, and evolving supplier catalog structure tracked closely over time and future cycles.
Gross Margin: 20-34%

Caffeine Citrate Therapies

The strategic watch-out, growing slowest at roughly 3.8% and facing steady commoditisation as standard apnea prevention applications become a bundled protocol component rather than a genuinely differentiated purchase decision across most regional tenders reviewed throughout this full analysis and its underlying data today and beyond.
Gross Margin: 18-30%

Recurring NICU Revenue Through Treatment Cycles

Treatment revenue increasingly behaves like an annuity layered on top of the original hospital formulary listing rather than a one-time transaction. Every protocol update, delivery method expansion, and clinical guideline renewal extends the supplier relationship well beyond initial adoption, and manufacturers with validated outcome data capture repeat prescribing with lower friction than switching to an unproven alternative therapy would require of a demanding neonatal care team.
Adoption depth varies considerably by end-use vertical. Large academic children's hospitals have the deepest, most established aerosolized adoption given research funding and clinical trial participation that make unconverted protocols extremely costly in reputational terms, while community hospital NICUs are earlier in adopting comparable outcome-documented therapies and still weighing procurement cost against demonstrated survival improvement. Regional referral centres sit differently, adopting premium cell-based platforms quickly given the recurring, high-stakes nature of extremely preterm care.

A generational shift is underway in neonatal care teams across most major markets. Younger neonatologists increasingly treat delivery method differentiation and outcome documentation as baseline prescribing requirements rather than differentiators, a shift that is compressing the commercial advantage early-adopting manufacturers once held over competitors still running largely corticosteroid-focused product catalogs.
bronchopulmonary-dysplasia-treatment-market-end-use-penetration-index-1787297960772

Where Manufacturers Should Focus Next

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / AEROSOLIZED DELIVERY BUNDLING

Bundled training programmes increasingly separate leaders from challengers

NICU programmes navigating increasingly demanding outcome reporting requirements increasingly prefer manufacturers who bundle aerosolized delivery systems with clinical training support, since that pairing reduces the programme's own procurement complexity considerably compared with sourcing devices and training separately from different vendors. That structure builds stickier customer relationships since switching suppliers mid-contract would force programmes to retrain neonatal staff entirely from scratch. Manufacturers without comparable training programmes remain exposed as hospitals increasingly expect integrated clinical support rather than devices alone, and that expectation only keeps hardening each cycle.
02 / CELL-BASED RESEARCH EXPANSION

Cell-based research capacity beats commodity corticosteroid volume

Cell-based therapy demand represents a considerably more defensible margin pool than standard corticosteroid demand alone could ever support, since cell-based treatment pricing commands roughly 7 times standard corticosteroid per-course value across most major producing markets tracked in this report. Companies expanding dedicated cell-based research capacity capture trial and launch contracts that generalist competitors increasingly cannot match, generating meaningful revenue through phased capacity conversion unfolding across multiple budget cycles. Building this capacity should rank above chasing standard corticosteroid tenders exclusively across every major NICU network.
03 / NICU NETWORK RELATIONSHIPS

Direct network relationships beat one-off hospital sales cycles

Hospital systems increasingly consolidate neonatal procurement through NICU network group purchasing, and manufacturers who maintain direct relationships with these networks capture recurring multi-hospital revenue considerably more predictable than one-off individual hospital sales alone ever provide across a comparable regional footprint. That relationship also generates early visibility into upcoming programme expansion cycles before competitors even learn a tender is coming their way. Building this relationship depth should rank above chasing every available individual hospital opportunity across the wider neonatal market and its unpredictable funding cycles.
04 / CHINESE MARKET EXPANSION

Early presence in Chinese NICU expansion compounds over time

Chinese treatment demand is scaling quickly as domestic hospital systems expand NICU capacity requiring validated pharmaceutical engineering meeting international quality standards across most major provincial hospital networks and their satellite clinics. Manufacturers establishing local distribution and clinical support presence early are winning multi-year hospital contracts before competitors relying solely on imported products can match local pricing and delivery turnaround. That early position compounds considerably as China's neonatal care sector keeps climbing through the remainder of the decade, rewarding early movers meaningfully over slower-moving competitors.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Bronchopulmonary Dysplasia Treatment Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Bronchopulmonary Dysplasia Treatment Exposure Evaluation 2025-26
CLIENT PROFILE
A regional children's hospital network operating six neonatal intensive care units engaged MMA while evaluating a system-wide aerosolized surfactant adoption strategy ahead of a planned capital budget cycle spanning the following two fiscal years. The client reported reliance on conventional instillation surfactant delivery across most of its units, with limited aerosolized capability concentrated at only its flagship academic centre (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether expanding aerosolized capability across all six units would reduce intubation rates faster than continuing the conventional instillation approach, while also weighing which manufacturers offered clinical training support flexible enough to sequence adoption across units without disrupting existing neonatal team workflows already familiar with current protocols.
MMA APPROACH
MMA benchmarked four qualified manufacturers on clinical evidence depth, training flexibility, and total lifecycle cost against the network's six-unit adoption plan in considerable detail. We modelled a phased rollout sequence prioritising the highest-volume units first across the network. We then assessed each manufacturer's clinical training support capacity given the client's aggressive adoption timeline.
KEY FINDINGS
  1. Converting the highest-volume units first would capture roughly 49% of projected intubation rate reduction within the programme's first full year of operation.
  2. Two of four candidate manufacturers could not guarantee clinical training capacity meeting the network's aggressive adoption timeline across all six units reliably or within budget.
  3. Expanded aerosolized adoption would reduce projected chronic lung disease incidence by an estimated 26% once fully operational across the entire converted unit network.
  4. The leading manufacturer's bundled clinical training programme would reduce the network's own staff onboarding burden by several weeks per unit site overall.
CLIENT PROFILE
A regional children's hospital network operating six neonatal intensive care units engaged MMA while evaluating a system-wide aerosolized surfactant adoption strategy ahead of a planned capital budget cycle spanning the following two fiscal years. The client reported reliance on conventional instillation surfactant delivery across most of its units, with limited aerosolized capability concentrated at only its flagship academic centre (client-reported, unverified by MMA).
STRATEGIC CHALLENGE
Leadership needed to decide whether expanding aerosolized capability across all six units would reduce intubation rates faster than continuing the conventional instillation approach, while also weighing which manufacturers offered clinical training support flexible enough to sequence adoption across units without disrupting existing neonatal team workflows already familiar with current protocols.
MMA APPROACH
MMA benchmarked four qualified manufacturers on clinical evidence depth, training flexibility, and total lifecycle cost against the network's six-unit adoption plan in considerable detail. We modelled a phased rollout sequence prioritising the highest-volume units first across the network. We then assessed each manufacturer's clinical training support capacity given the client's aggressive adoption timeline.
KEY FINDINGS
  1. Converting the highest-volume units first would capture roughly 49% of projected intubation rate reduction within the programme's first full year of operation.
  2. Two of four candidate manufacturers could not guarantee clinical training capacity meeting the network's aggressive adoption timeline across all six units reliably or within budget.
  3. Expanded aerosolized adoption would reduce projected chronic lung disease incidence by an estimated 26% once fully operational across the entire converted unit network.
  4. The leading manufacturer's bundled clinical training programme would reduce the network's own staff onboarding burden by several weeks per unit site overall.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 6 months): Finalise manufacturer selection and convert the highest-volume units identified across the entire hospital network first. Phase 2: Phase 2 (6 to 13 months): Complete remaining unit conversion sequenced around ongoing neonatal staffing and training commitments across all sites. Phase 3: Phase 3 (13 to 21 months): Complete full network conversion and renegotiate training terms under the newly established supply structure.
OUTCOME
The network completed priority unit conversion within the targeted seven-month window and reported intubation rate reduction tracking close to the modelled estimate across the converted unit network. Projected chronic lung disease incidence also declined measurably under the new procurement standard, though full twenty-one-month transition figures were not yet available at the time of reporting (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Bronchopulmonary Dysplasia Treatment Market?

The global bronchopulmonary dysplasia treatment market is valued at USD 0.9 billion in 2025, covering corticosteroid, surfactant, caffeine citrate, diuretic, bronchodilator, and emerging cell-based therapies.

How large will the Bronchopulmonary Dysplasia Treatment Market be by 2036?

The market is projected to reach USD 2.19 billion by 2036, roughly 2.24 times its 2026 value of USD 0.98 billion, driven by aerosolized surfactant adoption and cell-based therapy trials.

What is the CAGR for the Bronchopulmonary Dysplasia Treatment Market 2026 to 2036?

The base case CAGR is 8.4%, with a bull case of 9.6% if cell-based therapy trial data reads out favorably sooner, and a bear case of 7.2% under tighter hospital capital budgets.

Which segment is growing fastest?

Emerging Biologic and Cell-Based Therapies lead at a 14.5% CAGR, roughly 1.73 times the overall market rate, as neonatologists chase deeper lung tissue repair beyond corticosteroids and surfactant.

Who are the major companies in the Bronchopulmonary Dysplasia Treatment Market?

Chiesi, AbbVie, ONY Biotech, Windtree Therapeutics, and Fresenius Kabi lead the market, together holding roughly 48% of treatment revenue generated worldwide each year currently and reliably.

Which country is growing fastest?

China leads at a 11.8% CAGR as expanding NICU infrastructure and rising preterm birth survival pull volume toward domestic treatment programmes across major provinces nationwide.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Drug Therapy Class

  • Corticosteroid Therapies
  • Pulmonary Surfactant Therapies
  • Caffeine Citrate Therapies
  • Diuretic Therapies
  • Bronchodilator Therapies
  • Emerging Biologic and Cell-Based Therapies

By Treatment Setting

  • Academic Children's Hospitals
  • Community Hospital NICUs
  • Regional Referral Centres
  • Outpatient Follow-Up Care

By Commercial Dimension

  • Direct Hospital Sales
  • Group Purchasing Network Contracts
  • Distributor and Wholesale Channels
  • Research Partnership Deals

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The bronchopulmonary dysplasia treatment market covers corticosteroid, pulmonary surfactant, caffeine citrate, diuretic, bronchodilator, and emerging biologic or cell-based therapies used to prevent or treat chronic lung disease in preterm infants. It excludes mechanical ventilation equipment, general neonatal nutrition products, and treatments for unrelated respiratory conditions in older paediatric populations.
Quantitative Units
USD billions (current prices); annual treatment course volume where applicable
Segmentation Dimensions
By Drug Therapy Class; By Treatment Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Switzerland, Netherlands, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Italy, Spain, Sweden, Israel, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Chiesi Farmaceutici S.p.A., AbbVie Inc., ONY Biotech Inc., Windtree Therapeutics, Inc., Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Recordati S.p.A., Amring Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Aptar Pharma, Medipost Co., Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Perrigo Company plc, Novartis AG, Baxter International Inc.
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-147
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Bronchopulmonary Dysplasia Treatment Market Report (2026 to 2036).

The full report delivers granular sizing and forecasts across all six drug therapy segments and seven global regions through 2036. It profiles twenty companies across established generic manufacturers and specialist neonatal biotechs, benchmarking clinical evidence depth, manufacturing scalability, and distribution reach in considerable detail. Analysts detail biologic sourcing and delivery device cost exposure, portfolio margin tiers, and demand architecture by end-use vertical across major global markets and their evolving procurement environments. Buyers receive both the standalone report and full access to underlying data tables supporting every figure and forecast presented throughout.
Six-segment drug therapy sizing and full forecasts
Seven-region global market share breakdown detail
Twenty-company detailed competitive profile benchmarking analysis
Biologic sourcing cost exposure mitigation analysis
Portfolio margin tier benchmarking economics framework
Anonymised client engagement outcome case study

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts